1. 胃肠道肿瘤神经侵袭、神经-肿瘤交互作用及机制（Role of Perineural Invasion in GI cancer and possible mechanism）；

2. 胃肠道肿瘤能量代谢编程（Metabolic reprogramming of GI cancer）；

3. 胃肠道肿瘤微免疫环境与肿瘤转移机制（Tumor immune microenvironment and metastasis）；

4. 新药I期临床研究（anti-cancer new drug phase I clinical trial）

国家卫健委能力建设和继续教育肿瘤专家委员会 委员兼秘书

Secretary of National Health Commission Oncology Continuing Education Committee

中国医药创新促会抗肿瘤药物临床研究专业委员会 秘书长

Secretary of China Pharmaceutical Innovation and Research Development Association (PhIRDA) anti-tumor drug clinical research Committee

中国临床肿瘤学会（CSCO）药物安全管理专家委员会 常委兼秘书

Secretary and standing committee member of Anti-cancer drug Safety Management Committee (ASMC), CSCO

中国临床肿瘤学会（CSCO）青年委员会 常委兼秘书长

Secretary-general and standing committee member of CSCO YOUNG

中国临床肿瘤学会（CSCO）免疫治疗专家委员会 常委

Standing committee member of Immuno-Oncology Committee

中国临床肿瘤学会（CSCO）患者教育委员会 常委

Standing committee member of CSCO patients education committee

《肿瘤学杂志》 青年编委

Youth editor of

《肿瘤综合治疗电子杂志》 编委

Editor of

《Gastroenterology report》编委

Editor of < Gastroenterology report>

承担课题

1.2023年 国家自然科学基金，项目编号：82372922，MAGEA6促进结直肠癌嗜神经侵袭的作用及机制研究，起止时间：2024.01.01-2027.12.31；49万，在研，主持

2.2022年 国家自然科学基金，项目编号：82260562，转录因子ONECUT3通过增强结肠癌有氧糖酵解促进肿瘤进展的作用及机制研究，起止时间：2023.01.01-2026.12.31；33万，在研，主持

3.2021年 北京市希思科临床肿瘤学研究基金会，项目编号：Y-xsk2021-0003，XELOX方案联合瑞戈非尼及PD-1单抗一线治疗晚期胃癌的单臂、单中心临床研究，起止时间：2021.10-2024.9；30万，在研，主持

4.2021年 入选上海市浦东新区“优秀学科带头人”（浦东新区卫计委），项目编号：PWRd2021-09，起止时间：2021.11.01-2025.10.31，30万，在研，主持

5.2019年 上海市2019年度“科技创新行动计划”，项目编号：19DZ1910502，一类抗癌新药呋喹替尼联合信迪利单抗治疗晚期肝细胞癌患者的Ib/II期临床研究，起止时间：2019.10-2022.09；37.5万，在研，主持

1.2024.01.01-2027.12.31 Title: The role of MAGEA6 in colorectal cancer perineural invasion and possible mechanism.

Grant NO.: 82372922, PI (¥490,000), from NSFC

2.2023.01.01-2026.12.31 Title: Role of transcription factor ONECUT3 in promoting colon cancer progression by enhancing Warburg effect and possible mechanism.

Grant NO.: 82260562, PI (¥330,000), from NSFC

3.2021.10-2024.9, Title: XELOX plus Regorafenib and PD-1 antibody for the first line treatment in advancec gastric caner: a single arm, single center clinical trial.

Grant NO.: Y-xsk2021-0003, PI (¥300,000), from CSCO Grant committee.

4.2021.11-2025.10 Academic Leaders Training Program of Pudong Health Bureau of Shanghai

Grant NO.: PWRd2021-09, PI (¥300,000), from Pudong Health Bureau of Shanghai.

5.2019.10-2022.09 Title: Phase I/II clinical trial of Fruquitinib and Sintilimab combination strategy in advanced hepatocellular cell carcinoma.

Grant NO.: 19DZ1910502, PI (¥375,000), from the Science and Technology Commission of Shanghai Municipality.

发表论文：

1.Minhao Yu#, Hao Wang#, Wei Zhao#, Xiaoxiao Ge, Wei Huang, Fengjuan Lin, Wenbo Tang, Ang Li1, Sailiang Liu, Rong-Kun Li*, Shu-Heng Jiang*, Junli Xue*. Targeting type Iγ phosphatidylinositol phosphate kinase overcomes oxaliplatin resistance in colorectal cancer. Theranostics. 2022; 12(9): 4386-4398. doi: 10.7150/thno.69863.

2.Wei Peng, Wei Huang, Liqiong Xue, Xiaoxiao Ge, Wei Zhao, Junli Xue*. Type Iγ phosphatidylinositol phosphate kinase promotes tumor growth by facilitating Warburg effect in colorectal cancer. EBioMedicine, 2019, 44: 375-386.

3.He K, Wang H, Huo R, Jiang SH, Xue J*. Schwann cells and enteric glial cells: Emerging stars in colorectal cancer. Biochim Biophys Acta Rev Cancer. 2024 Jul 24;1879(5):189160. doi: 10.1016/j.bbcan.2024.189160. Epub ahead of print. PMID: 39059672.

4.Wang H#, Huo R#, He K#, Cheng L, Zhang S, Yu M, Zhao W*, Li H*, Xue J*. Perineural invasion in colorectal cancer: mechanisms of action and clinical relevance. Cell Oncol (Dordr). 2023 Aug 23. doi: 10.1007/s13402-023-00857-y. Epub ahead of print. PMID: 37610689.

5.Xue J, Xue L, Tang W, Ge X, Zhao W, Li Q, Peng W, Dai C, Guo Y, Li J. TQB2450 in patients with advanced malignant tumors: results from a phase I dose-escalation and expansion study. Ther Adv Med Oncol. 2024 Jan 6;16:17588359231220516. doi: 10.1177/17588359231220516. PMID: 38188467; PMCID: PMC10771754.

6.Shuheng Jiang#*, Shan Zhang#, Hao Wang#, Junli Xue*, Zhigang Zhang*. Emerging experimental models for assessing perineural invasion in human cancers. Cancer Lett. 2022 Mar 10:215610. doi: 10.1016/j.canlet.2022.215610. Epub ahead of print. PMID: 35283209.

7.Qinghe Tang, Wei Huang, Jun Liang, Junli Xue*. Efficacy and Safety of Transarterial Chemoembolization in Elderly Patients of Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Retrospective Study. Front Oncol. 2021 Jul 7;11:646410. doi: 10.3389/fonc.2021.646410. PMID: 34307128; PMCID: PMC8293292.

8.JunLi Xue, XiaoXiao Ge, Wei Zhao, Liqiong Xue, Congqi Dai, Fengjuan Lin, and Wei Peng. PIPKIγ Regulates CCL2 Expression in Colorectal Cancer by Activating AKT-STAT3 Signaling. Journal of Immunology Research, 2019, 3690561, 2019 Nov 3, eCollection 2019.

9.Junli Xue, Xuetao Yu⁠, ⁠Liqiong Xue, Xiaoxiao Ge, Wei Zhao, Wei Peng. Intrinsic β-catenin signaling suppresses CD8⁠+ T-cell infiltration in colorectal cancer. Biomedicine & Pharmacotherapy. 2019, 115: 108921.

10.Xu Liang#, Junli Xue#, Xiaoxiao Ge, Jin Li, Huiping Li, Liqiong Xue, Lijun Di, Wenbo Tang, Guohong Song, Qun Li, Hanfang Jiang, Wei Zhao, Fengjuan Lin, Bin Shao, Xiugao Yang, Zhufeng Wu, Tianyi Zhang, Chenchen Wang, Ye Guo*. Safety, tolerability, and pharmacokinetics/pharmacodynamics of JMT103 in patients with bone metastases from solid tumors. Front Oncol. 2022 Aug 5;12:971594. doi: 10.3389/fonc.2022.971594. PMID: 35992822; PMCID: PMC9389458.

11.Peng Wang#, Junli Xue#, Shengming Wu, Yanbai Pei, Lehua Xu, and Yilong Wang*. Cell-Friendly Isolation and pH-Sensitive Controllable Release of Circulating Tumor Cells by Fe3O4@CaCO3 Nanoplatform. Adv. Mater. Interfaces 2021, 2101191.

12.Shuheng Jiang#, Rong-Kun Li#, De-Jun Liu#, Jun-Li Xue#, Min-Hao Yu#, Shan Zhang, Li-Min Liu, Jun-Feng Zhang, Rong Hua, Yong-Wei Sun, Xu Wang*, Qin Yang*, Zhigang Zhang*. The genomic, transcriptomic, and immunological profiles of perineural invasion in pancreatic ductal adenocarcinoma. SCIENCE CHINA Life Sciences (2022); doi: 10.1007/s11427-022-2146-5.